165 related articles for article (PubMed ID: 28005274)
21. Tumor-free osteosclerotic lesions in patients treated for metastatic melanoma using BRAF inhibitors.
Bottlaender L; Perier-Muzet M; Lapras V; Thomas L; Dalle S
Melanoma Res; 2017 Feb; 27(1):68-71. PubMed ID: 27759578
[TBL] [Abstract][Full Text] [Related]
22. Panniculitis in patients treated with BRAF inhibitors: a case series.
Choy B; Chou S; Anforth R; Fernández-Peñas P
Am J Dermatopathol; 2014 Jun; 36(6):493-7. PubMed ID: 24879511
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of BRAFi-induced hyperproliferative cutaneous conditions.
Ali M; Anforth R; Senetiner F; Carlos G; Fernandez-Penas P
Exp Dermatol; 2016 May; 25(5):394-5. PubMed ID: 26896751
[No Abstract] [Full Text] [Related]
24. A case report of neutrophilic eccrine hidradenitis in a patient receiving chemotherapy for acute myeloid leukaemia.
Wong GC; Lee LH; Chong YY
Ann Acad Med Singap; 1998 Nov; 27(6):860-3. PubMed ID: 10101565
[TBL] [Abstract][Full Text] [Related]
25. Novel melanoma therapies and their side effects.
González N; Ratner D
Cutis; 2016 Jun; 97(6):426-8. PubMed ID: 27416087
[TBL] [Abstract][Full Text] [Related]
26. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
Lacroix JP; Wang B
J Cutan Med Surg; 2017; 21(1):54-59. PubMed ID: 27624900
[TBL] [Abstract][Full Text] [Related]
27. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.
Park JJ; Hawryluk EB; Tahan SR; Flaherty K; Kim CC
JAMA Dermatol; 2014 Mar; 150(3):307-11. PubMed ID: 24352115
[TBL] [Abstract][Full Text] [Related]
29. Neutrophilic eccrine hidradenitis: a new culprit-carbamazepine.
Bhanu P; Santosh KV; Gondi S; Manjunath KG; Rajendaran SC; Raj N
Indian J Pharmacol; 2013; 45(1):91-2. PubMed ID: 23543588
[TBL] [Abstract][Full Text] [Related]
30. Neutrophilic eccrine hidradenitis mimicking cutaneous vasculitis in a lupus patient: a complication of cyclophosphamide.
Lienesch DW; Mutasim DF; Singh RR
Lupus; 2003; 12(9):707-9. PubMed ID: 14514135
[TBL] [Abstract][Full Text] [Related]
31. Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib.
Jhaveri KD; Sakhiya V; Fishbane S
JAMA Oncol; 2015 Nov; 1(8):1133-4. PubMed ID: 26182194
[TBL] [Abstract][Full Text] [Related]
32. Neutrophilic eccrine hidradenitis: report of two cases.
Kanzaki H; Oono T; Makino E; Arata J; Oda M; Akazai A
J Dermatol; 1995 Feb; 22(2):137-42. PubMed ID: 7722091
[TBL] [Abstract][Full Text] [Related]
33. [Adult idiopathic neutrophilic eccrine hidradenitis treated with colchicine].
Belot V; Perrinaud A; Corven C; de Muret A; Lorette G; Machet L
Presse Med; 2006 Oct; 35(10 Pt 1):1475-8. PubMed ID: 17028536
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.
Anforth RM; Blumetti TC; Kefford RF; Sharma R; Scolyer RA; Kossard S; Long GV; Fernandez-Peñas P
Br J Dermatol; 2012 Nov; 167(5):1153-60. PubMed ID: 22804352
[TBL] [Abstract][Full Text] [Related]
35. Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive.
Gabeff R; Dutartre H; Khammari A; Boisrobert A; Nguyen JM; Quereux G; Brocard A; Saint-Jean M; Peuvrel L; Dreno B
Eur J Dermatol; 2015; 25(5):452-6. PubMed ID: 26242321
[TBL] [Abstract][Full Text] [Related]
36. Chronic pruritic neutrophilic eccrine hidradenitis in a patient with Behçet's disease.
Nijsten TE; Meuleman L; Lambert J
Br J Dermatol; 2002 Oct; 147(4):797-800. PubMed ID: 12366434
[TBL] [Abstract][Full Text] [Related]
37. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
38. Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors.
Erfan G; Puig S; Carrera C; Arance A; Gaba L; Victoria I; Garcia-Herrera A; Alos L; Malvehy J
Acta Derm Venereol; 2017 Feb; 97(2):258-260. PubMed ID: 27353949
[No Abstract] [Full Text] [Related]
39. Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.
Amaravadi RK; Hamilton KE; Ma X; Piao S; Portillo AD; Nathanson KL; Carlino MS; Long GV; Puzanov I; Xu X; Morrissette JJ; Tsai KY; Flaherty KT; Sosman JA; Goodman GR; McArthur GA; Rustgi AK; Metz DC; Schuchter LM; Chapman PB; Sepulveda AR
Clin Cancer Res; 2015 Dec; 21(23):5215-21. PubMed ID: 26202952
[TBL] [Abstract][Full Text] [Related]
40. A case of vemurafenib-induced keratosis pilaris-like eruption.
Wang CM; Fleming KF; Hsu S
Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
